Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

1 minuto di lettura

(Adnkronos) – PARIS, Feb. 24, 2023 /PRNewswire/ — Servier, a global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Tibsovo® (ivosidenib tablets) – an inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) enzyme – for two indications: 


Claude Bertrand, Executive Vice President R&D of Servier, said: “The positive CHMP opinion is a further step towards the availability, in the European Union, of Tibsovo® which is the first IDH1 inhibitor to be recommended for approval in Europe for patients with Acute Myeloid Leukemia and Cholangiocarcinoma for whom therapeutic options are very limited. Tibsovo® is an illustration of the Group’s transformation and commitment in oncology which focuses its research on hard-to-treat cancers with the development of targeted therapies being a promising path for patients.”  

The positive CHMP opinion is based on clinical data from the AGILE (AML) and ClarIDHy (CCA) studies. 

The CHMP’s positive opinion on Tibsovo® in IDH1 mutated AML and CCA patients will be referred to the European Commission (EC) which will deliver a final decision in the coming months. The decision will be applicable to all 27 EU member states plus Iceland, Norway, Northern Ireland and Liechtenstein. 

PDF – –



View original content to download multimedia:


Lascia un commento

Your email address will not be published.

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.

Articolo precedente

Al via la prima edizione di BCO ZERO WEEK: attivo il numero verde per prenotare Consulenze gratuite in 40 centri specialistici

Articolo successivo

E’ morto Maurizio Costanzo, aveva 84 anni

0  0,00